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Abstract
Background:  Ciclesonide is a novel inhaled corticosteroid for the treatment of airway
inflammation. In this study we investigated uptake and in vitro metabolism of ciclesonide in human
alveolar type II epithelial cells (A549). Ciclesonide uptake was compared with fluticasone
propionate, an inhaled corticosteroid that is not metabolized in lung tissue. A549 cells were
incubated with 2 × 10-8 M ciclesonide or fluticasone propionate for 3 to 30 min to determine
uptake; or with 2 × 10-8 M ciclesonide for 1 h, followed by incubation with drug-free buffer for 3,
6, and 24 h to analyze in vitro metabolism. High performance liquid chromatography with tandem
mass spectrometry was used to measure the concentrations of both corticosteroids and
metabolites.
Results: At all time points the mean intracellular concentration was higher for ciclesonide when
compared with fluticasone propionate. Activation of ciclesonide to desisobutyryl-ciclesonide (des-
CIC) was confirmed and conjugates of des-CIC with fatty acids were detected. The intracellular
concentration of ciclesonide decreased over time, whereas the concentration of des-CIC remained
relatively stable: 2.27 to 3.19 pmol/dish between 3 and 24 h. The concentration of des-CIC fatty
acid conjugates increased over time, with des-CIC-oleate being the main metabolite.
Conclusion: Uptake of ciclesonide into A549 cells was more efficient than that of the less
lipophilic fluticasone propionate. Intracellular concentrations of the pharmacologically active
metabolite des-CIC were maintained for up to 24 h. The local anti-inflammatory activity of
ciclesonide in the lung may be prolonged by the slow release of active drug from the depot of fatty
acid esters.
Background
Modern inhaled corticosteroids are currently the most
effective drugs used in long-term asthma therapy, com-
bining potent anti-inflammatory activity with fast meta-
bolic inactivation [1,2]. Inhaled corticosteroids can
reduce bronchial hyperresponsiveness, asthma symp-
toms, frequency of asthma exacerbations, and improve
lung function and quality of life [3]. On the other hand,
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long-term treatment with inhaled corticosteroids can be
associated with systemic adverse effects, such as cortisol
suppression, formation of cataracts, decreased bone den-
sity, and growth suppression in children [3].
The efficacy of an inhaled corticosteroid and its potential
to cause systemic adverse effects are based on its pharma-
codynamic and pharmacokinetic properties [3-5]. These
properties are determined by the reversible binding of the
drug to the glucocorticoid receptor, which is present in
almost all cell types [3]. Thus, local therapeutic benefits as
well as unwanted adverse effects are mediated by the same
receptor [6].
Ciclesonide is a new generation inhaled corticosteroid for
the treatment of asthma and allergic rhinitis [7-9]. In con-
trast to other inhaled corticosteroids that bind directly to
the glucocorticoid receptor, e.g. fluticasone propionate,
ciclesonide is a prodrug with almost no receptor binding
affinity. Airway esterases convert ciclesonide to its phar-
macologically active metabolite desisobutyryl-ciclesonide
(des-CIC), which has a 100-fold higher binding affinity
for the glucocorticoid receptor than its parent compound
[7,10]. The receptor binding affinity varies among inhaled
corticosteroids and is expressed as the binding affinity rel-
ative to dexamethasone with an affinity of 100 [4]. Des-
CIC and fluticasone propionate are among the most
potent corticosteroids with binding affinities relative to
dexamethasone of 1200 and 1800, respectively [11].
Before a corticosteroid is able to bind to its receptor, it has
to pass through the phospholipid bilayer of the cell mem-
brane. The efficacy of an inhaled corticosteroid therefore
also depends on its efficient uptake into the cell. Several
features of the drug, such as the size of the molecule,
charge, and lipophilicity play a role in its ability to cross
this barrier. High lipophilicity may also enhance receptor
binding affinity and this property correlates highly with
the volume of distribution and pulmonary retention time
of the drug [12,13]. Prolonging the time that a drug is
available in the lung may enhance its anti-inflammatory
activity. The conjugation of a corticosteroid with highly
lipophilic fatty acids in the pulmonary tissue is a mecha-
nism by which the retention time of a drug is increased
[14]. The ester bond between the corticosteroid and the
fatty acid is formed via a hydroxyl group at position C-21
[15]. Des-CIC, but not fluticasone propionate, has the
required group at position C-21 (Figure 1). Conjugates of
des-CIC with oleic and palmitic acid have been found in
vitro and in vivo in rat and human lung tissues [16-18]. The
formation of these pharmacologically inactive des-CIC
fatty acid esters is a reversible process [17].
The objective of this study was to investigate the uptake of
ciclesonide in human alveolar typeII epithelial cells, using
the human-lung derived carcinoma A549 cell line as an
established in vitro model for studying drug metabolism
and delivery in the lung epithelium [19]. Ciclesonide
uptake was compared with the uptake of fluticasone pro-
pionate, a potent and widely used inhaled corticosteroid
[20]. In addition, the in vitro metabolism of ciclesonide in
A549 cells was examined, to evaluate the formation of the
pharmacologically active metabolite des-CIC and its con-
jugation with fatty acids in human lung epithelial cells.
Results
Uptake of ciclesonide and fluticasone propionate in A549 
cells
The mean intracellular concentrations of ciclesonide and
fluticasone propionate determined by LC/MS/MS analysis
after 3, 5, 10, 20, and 30 min of incubation are shown in
Table 1 and Figure 2. After 30 min, most of the ciclesonide
was not metabolized. The parent compound accounted
Chemical structures of the parent compound ciclesonide, its  active metabolite desisobutyryl-ciclesonide (des-CIC), des- CIC fatty acid conjugates, and fluticasone propionate Figure 1
Chemical structures of the parent compound cicleso-
nide, its active metabolite desisobutyryl-ciclesonide 
(des-CIC), des-CIC fatty acid conjugates, and flutica-
sone propionate. * Hydroxyl group of des-CIC at position 
C-21.
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Table 1: Intracellular concentrations of ciclesonide, des-CIC, and 
des-CIC-oleate during incubation with 2 × 10-8 M ciclesonide
Incubation 
time (min)
Mean concentration ± SD (pmol/dish)a)
Ciclesonide des-CIC des-CIC-
oleateb)
3 15.04 ± 2.48 0.41 ± 0.05 0.00 ± 0.00
5 17.86 ± 2.30 0.33 ± 0.19 0.00 ± 0.00
10 36.63 ± 23.48 0.67 ± 0.13 0.02 ± 0.05
20 34.22 ± 9.15 0.97 ± 0.14 0.12 ± 0.07
30 48.21 ± 5.19 1.72 ± 0.14 0.40 ± 0.06
a) 5 dishes per time point
b) Conjugates of des-CIC with palmitic acid were almost 
undetectable.BMC Pharmacology 2007, 7:12 http://www.biomedcentral.com/1471-2210/7/12
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for 96% of the total amount of ciclesonide (parent com-
pound plus metabolites). At this time point, the total con-
centration of ciclesonide in A549 cells was 2.1-fold higher
than the concentration of fluticasone propionate; the dif-
ference was statistically significant (p < 0.001). At all other
time points, the concentration of ciclesonide was numer-
ically higher when compared with fluticasone propionate
(1.1- to 1.9-fold).
In vitro metabolism of ciclesonide in A549 cells
Because the majority of ciclesonide (96%) was not metab-
olized during 30 min of incubation, we investigated the
metabolism of ciclesonide during a longer period of time.
The mean intracellular concentrations of the parent com-
pound ciclesonide, its active metabolite des-CIC and fatty
acid conjugates of des-CIC after 3, 6, and 24 h of drug-free
incubation are shown in Figure 3. Ciclesonide concentra-
tions decreased over time from 24.17 ± 3.29 pmol/dish
after 3 h to approximately 1/10th of that level after 24 h
(2.31 ± 0.55 pmol/dish). The mean intracellular concen-
trations of des-CIC remained about constant during the
24-h incubation period, with values of 2.27 ± 0.25, 3.10 ±
0.38, and 3.19 ± 0.38 pmol/dish after 3, 6 and 24 h of
incubation. Lipid conjugates of des-CIC with oleic acid
and palmitic acid were detected. At all time points, the
main metabolite of ciclesonide was des-CIC-oleate. The
concentrations of the des-CIC fatty acid conjugates in the
A549 cells increased over time. Des-CIC-oleate concentra-
tions increased from 6.61 ± 1.25 pmol/dish after 3 h to
23.20 ± 6.03 pmol/dish after 24 h of incubation. Des-CIC-
palmitate concentrations were much lower, but showed
an increase from 0.08 ± 0.08 pmol/dish to 0.74 ± 0.15
pmol/dish measured after 3 and 24 h, respectively.
Discussion
In asthma therapy, alveolar epithelial cells are one of the
most important targets for inhaled corticosteroids,
because these cells are involved in the secretion of many
pro-inflammatory proteins [21,22]. Thus, the efficient
uptake of an inhaled corticosteroid into these cells is a
prerequisite for the exertion of its anti-inflammatory
activity. The human epithelial lung adenocarcinoma cell
line A549 provides a useful model for drug transport and
metabolic processes in epithelial type II cells [19]. In this
study we evaluated the uptake efficiency of the two corti-
costeroids ciclesonide and fluticasone propionate into
A549 cells and investigated the metabolism of ciclesonide
in this cell type.
After incubation, significantly higher concentrations of
ciclesonide than fluticasone propionate were detected in
A549 cells, suggesting a more efficient uptake of cicleso-
nide into the cells (p < 0.001). These observations might
be correlated with the lipophilicity of the compounds.
High lipophilicity facilitates the passage of the drug
through the phospholipid bilayer of the cell. The logD
(logarithm of the effective partition coefficient for dissoci-
ative systems in octanol-water) values at pH 7.4 are 5.0 for
ciclesonide and 4.1 for fluticasone propionate, indicating
that ciclesonide has a 7.9-fold higher lipophilicity com-
pared with fluticasone propionate.
Intracellular concentrations of ciclesonide, des-CIC, des- CIC-oleate, and des-CIC-palmitate in A549 cells during 24 h  of incubation with drug-free buffer Figure 3
Intracellular concentrations of ciclesonide, des-CIC, 
des-CIC-oleate, and des-CIC-palmitate in A549 cells 
during 24 h of incubation with drug-free buffer. 
Results represent the mean ± standard deviation from 5 
dishes per time point.
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Intracellular concentrations of ciclesonide and fluticasone  propionate in A549 cells during incubation with 2 × 10-8 M  ciclesonide or fluticasone propionate Figure 2
Intracellular concentrations of ciclesonide and fluti-
casone propionate in A549 cells during incubation 
with 2 × 10-8 M ciclesonide or fluticasone propionate. 
Concentrations of ciclesonide represent the sum of the 
intracellular concentrations of ciclesonide, des-CIC, and fatty 
acid esters of des-CIC. Results represent the mean ± stand-
ard deviation from 5 dishes per time point. *** p < 0.001 for 
ciclesonide versus fluticasone propionate (Aspin-Welch t-
test).
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Binding of drugs to plasma proteins is another factor that
may affect the uptake of drugs into cells. In the systemic
circulation, 99% of ciclesonide and 90% of fluticasone
propionate are protein-bound [11], leading to the
assumption that in vivo more unbound fluticasone propi-
onate is available for uptake compared with ciclesonide.
However, the protein content of the incubation media in
these experiments was 0.1% BSA, which is lower than the
protein content in the systemic circulation. Furthermore,
the exact protein concentration in vivo on the surface of
alveolar cells is not known. Therefore, it is not certain
whether the difference in protein binding between the
two corticosteroids might have an influence on the results
of this study.
After the uptake into the A549 cells, ciclesonide is con-
verted by airway esterases to its pharmacologically active
metabolite des-CIC, which is then conjugated with fatty
acids. During the 24-h drug-free incubation period, the
intracellular levels of des-CIC remained stable, while
ciclesonide concentrations decreased to trace amounts at
24 h and levels of des-CIC fatty acid conjugates increased
over time. Des-CIC-oleate was the major fatty acid conju-
gate, and after 24 h of drug-free incubation, the major
compound detected. Similar results were reported previ-
ously in vitro for precision-cut human lung slices and for
human lung tissue after in vivo inhalation of ciclesonide
[18,23]. The total amount of intracellular ciclesonide
(sum of ciclesonide, des-CIC, and des-CIC-oleate)
remained stable over the 24 h of drug-free incubation. In
a previous study using similar experimental conditions,
the anti-inflammatory potency of des-CIC in A549 cells
was demonstrated by the inhibition of cytokine produc-
tion [24].
Conclusion
Overall, this study demonstrated that ciclesonide is effec-
tively taken up into human alveolar type II epithelial
(A549) cells and metabolized to its pharmacologically
active metabolite des-CIC and fatty acid conjugates of des-
CIC. Levels of des-CIC remained constant over a 24 h
period, possibly because des-CIC may be formed from
either ciclesonide or des-CIC-oleate. Fatty acid esters are
much more lipophilic compared with the parent com-
pound ciclesonide [16]. These inactive esters remain in
the cells, where they reconvert to the active metabolite,
thus prolonging the exposure time and local anti-inflam-
matory activity of ciclesonide in the lung. The slow-release
pool of active drug may contribute to the proven efficacy
of once-daily inhaled ciclesonide in asthma therapy, as
was shown in several clinical studies [25-30].
Methods
Cells and materials
Human alveolar type II epithelial cells (A549) were
obtained from Dainippon Pharmaceutical Co., Ltd.
(Osaka. Japan). Ciclesonide, des-CIC, des-CIC-oleate,
des-CIC-palmitate, deuterium-labeled des-CIC, and fluti-
casone propionate were supplied by ALTANA Pharma AG
(Konstanz, Germany). Dulbecco's Modified Eagle
Medium (DMEM), Dulbecco's phosphate-buffered saline
(PBS), fetal bovine serum (FBS), and antibiotics were pur-
chased from Invitrogen/GIBCO (Tokyo, Japan). Bovine
serum albumin (BSA), ammonium acetate, and HPLC-
grade ethanol (99.5%) were from Wako Pure Chemicals
Industries, Ltd. (Osaka, Japan). Ethylenediamine-N, N,
N', N'-tetraacetic acid tetrasodium salt (EDTA-4Na) was
supplied by Dojin Laboratories, Inc. (Kumamoto, Japan).
Acetonitrile was from Fisher Scientific Japan, Co. Ltd.
(Tokyo, Japan), and trypsin/EDTA and trypsin neutraliz-
ing solution from Sanko Junyaku Co., Ltd. (Tokyo,
Japan).
Cell culture conditions
A549 cells were grown in DMEM supplemented with 10%
(v/v) FBS at 37°C and saturated humidity (5% CO2, 95%
air) in a CO2 incubator (Wakenyaku Co., Ltd., Kyoto,
Japan) using 10 cm culture dishes. When confluence was
reached, medium was replaced by DMEM/0.1% (w/v)
BSA and cells were cultured for 24 h.
Uptake of corticosteroids
After initial cultivation, A549 cells were washed twice with
10 ml/dish sterile PBS. Stock solutions of ciclesonide and
fluticasone propionate were prepared using HPLC-grade
ethanol and diluted 1000-fold with assay medium to gen-
erate the initial substrate concentration. The cells were
incubated in DMEM/0.1%(w/v) BSA (5 ml/dish) with 2 ×
10-8 M ciclesonide or fluticasone propionate for 3, 5, 10,
20, or 30 min. At the end of the incubation period, the
medium was removed by aspiration, dishes were washed
five times with ice-chilled PBS (10 ml/dish) and incu-
bated with 5 mM EDTA-4Na/PBS for further 5 minutes in
the CO2  incubator. The cells were detached from the
dishes and harvested. Each dish was washed five times
with ice-chilled PBS. The cell pellets obtained by centrifu-
gation (Kubota 8700: 1500 rpm, 5 min, 4°C) were frozen
in liquid nitrogen and kept at -80°C until further use.
Metabolism of ciclesonide
After initial cultivation, A549 cells were washed five times
with 10 ml/dish sterile PBS. An ethanolic stock solution of
ciclesonide was diluted 1000-fold with assay medium to
generate the initial ciclesonide concentration The cells
were incubated for 1 h in DMEM/0.1% (w/v) BSA (5 ml/
dish) containing 2 × 10-8 M ciclesonide as described above
in a CO2 incubator. At the end of the incubation period,BMC Pharmacology 2007, 7:12 http://www.biomedcentral.com/1471-2210/7/12
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dishes were washed five times with PBS and incubated for
3, 6, or 24 h at the same conditions in 5 ml/dish fresh
medium (DMEM/0.1% (w/v) BSA). At each indicated
time point, the medium was removed by aspiration, 5
mM EDTA-4Na/PBS added and dishes were incubated for
further 5 min. The cells were detached from the dishes and
harvested. Each dish was washed five times with ice-
chilled PBS. The cell pellets obtained by centrifugation
were frozen in liquid nitrogen and kept at -80°C until fur-
ther use.
Preparation of cell extracts
Cell pellets were homogenized in 0.8 ml ethanol using an
ultrasonic homogenizer (Sonifier 250, Branson Ultrason-
ics Corporation, Danbury, Conn, USA). After centrifuga-
tion for 15 min at 4°C, aliquots of the supernatant were
stored at -20°C until further use.
Liquid chromatography and tandem mass spectrometry 
(LC/MS/MS)
Ciclesonide, des-CIC, des-CIC fatty acid conjugates, and
fluticasone propionate were separated by high perform-
ance liquid chromatography (HPLC; Agilent HP1100,
Agilent Technologies, Tokyo, Japan) using a 5µm Hyper-
sil® Phenyl 2 column (50 × 4.6 mm; Thermo Electron,
K.K., Yokohama, Japan) The mobile phase consisted of
25% (v/v) acetonitrile/purified water/1 mM ammonium
acetate and 95% (v/v) acetonitrile/purified water/1 mM
ammonium acetate at a flow rate of 1.0 ml/min for a total
run time of 7 min. As an internal standard, an analogue of
des-CIC carrying a deuterium label at the cyclohexyl
group was used. The analytes were detected by a tandem
mass spectrometry system (API3000, Applied Biosystems,
Tokyo, Japan) with a turbo ion spray source and negative
multiple reaction monitoring scan mode.
Data analysis
The concentrations of ciclesonide, fluticasone propionate,
and metabolites in the assay samples were determined by
comparing calibration curves using the Analyst 1.1 data
processing program. The calibration curves were drawn
from the primary regression line determined by the least-
squares method (weighting factor: 1/x). The lower limits
of quantification (LLOQ), determined from the calibra-
tion curves, were defined as 0.10 ng/ml for ciclesonide
and des-CIC-oleate, 0.20 ng/ml for des-CIC and des-CIC-
palmitate, and 0.40 ng/ml for fluticasone propionate.
Differences in concentrations between samples treated
with either ciclesonide or fluticasone dipropionate were
determined by using the Aspin Welch t-test. The concen-
trations are given as mean ± standard deviation.
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